COMMAND: A phase II randomized, double-blind, placebo-controlled, multicenter study of defactinib as maintenance therapy in subjects with malignant pleural mesothelioma that has not progressed on at least four cycles of pemetrexed/platinum therapy.
Dean Anthony Fennell
Honoraria - Verastem
Paul Baas
Honoraria - Verastem
Hedy Lee Kindler
Honoraria - Verastem
Lee M. Krug
Honoraria - Verastem
Anna Nowak
Honoraria - Verastem
Marjorie Zauderer
Honoraria - Verastem
Richard J. Gralla
Honoraria - Verastem
Mitchell Keegan
Employment or Leadership Position - Verastem
Stock Ownership - Verastem
Joanna Horobin
Employment or Leadership Position - Verastem
Stock Ownership - Verastem